A study has revealed that a budgetary saving per treated patient with the fluocinolone acetonide implant (Iluvien) versus ranibizumab (Lucentis) could lead to a significant cost-saving to NHS England.
Dr Fahd Quhill
Advertisement
Articles by Dr Fahd Quhill
Advertisement
Latest Updated Articles
- Intravitreal implant could bring significant cost savings to NHS England
February 26th 2018
Advertisement
Advertisement
Trending on Eye Care Network - Ophthalmology Times
1
FDA grants RMAT designation to Emmecell's EO2002 for corneal endothelial disease
2
NeuroOp Guru: What a big data study reveals about NAION and stroke risk
3
Port Delivery System Therapies in Retinal Vascular Diseases
4
Offline smartphone AI accurately detects DR, glaucoma, and AMD in real-world study
5